echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > my country's own original lung cancer targeted drugs show advantages in treating lung cancer brain metastases

    my country's own original lung cancer targeted drugs show advantages in treating lung cancer brain metastases

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Medical Network News, March 24, recently, China's independent research and development of the third-generation lung cancer targeted therapy for EGFR (epidermal growth factor receptor) mutations Ivesa (Vometinib mesylate) was awarded the National Medical Products Administration Approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with targeted drugs for EGFR mutations and confirmed to have EGFR T790M mutation-positive
    .
    Aifusha is a national class 1 new drug originally developed in China with independent intellectual property rights

    .
    According to the Chinese Academy of Medical Sciences
    Tumor Hospital, vice president Professor Shi Yuankai believes Yifu Sha approved only for patients with advanced NSCLC is a domestic Gospel, but also for reducing the mortality of lung cancer is also a great good news
    .
    In recent years, first-generation and second-generation drugs against EGFR targets associated with significantly improved advanced NSCLC without EGFR mutations in
    disease progression-free survival, but failed to bring significant change to this part of the overall survival of patients with advanced lung cancer, Moreover, patients receiving first-generation EGFR-TKI treatment are more likely to develop brain metastases than patients receiving chemotherapy.
    Once lung cancer brain metastases occur, the median survival time of patients who do not receive any treatment is only 2 months

    .
    Therefore, the control and even prevention of lung cancer brain metastasis has become a medical core to reduce the recurrence and mortality of advanced lung cancer

    .
    Professor Yuankai Shi pointed out that the third-generation EGFR-TKI has been recommended by authoritative lung cancer diagnosis and treatment guidelines in the United States and China as a first-line treatment for EGFR-sensitive mutations and T790M-mutated NSCLC.
    The original third-generation EGFR-TKI treatment obtained survival benefits and contributed to reducing the high mortality rate of lung cancer in China

    .
    It is reported that recently, Beijing Kangmeng Charity Foundation has launched the Aifusha Patient Assistance Project ("Fuyao" Newborn) to reduce the drug burden of lung cancer patients in China

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.